Guidelines
- American Diabetes Association. Standards of Care in Diabetes — updated annually. Diabetes Care.
- AACE / ACE. Clinical Practice Guidelines for Comprehensive Medical Care of Patients with Obesity. Endocr Pract.
- Eisenberg D et al. 2022 ASMBS and IFSO Indications for Metabolic and Bariatric Surgery. Surg Obes Relat Dis, 2022.
- EASD / EASO joint statements on obesity and type 2 diabetes.
Surgery vs. medical therapy — pivotal trials
- Schauer PR et al. Bariatric surgery vs. intensive medical therapy for diabetes — 5-year outcomes. NEJM, 2017.
- Mingrone G et al. Metabolic surgery vs. conventional medical therapy in obese patients with type 2 diabetes: 10-year follow-up. Lancet, 2021.
- Sjöström L et al. Effects of bariatric surgery on mortality in Swedish Obese Subjects. NEJM, 2007.
- Adams TD et al. Weight and metabolic outcomes 12 years after gastric bypass. NEJM, 2017.
Pharmacotherapy
- Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP-1). NEJM, 2021.
- Rubino D et al. STEP-4: Effect of continued weekly semaglutide vs. placebo on weight maintenance. JAMA, 2021.
- Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). NEJM, 2022.
- Aronne LJ et al. Continued treatment with tirzepatide for maintenance of weight reduction (SURMOUNT-4). JAMA, 2024.
Mechanism and safety
- Rubino F et al. Metabolic surgery in the treatment algorithm for type 2 diabetes: joint statement by international diabetes organizations. Diabetes Care, 2016.
- Arterburn DE et al. Association between bariatric surgery and long-term survival. JAMA, 2015.
- Courcoulas AP et al. Long-term outcomes of medical management vs. bariatric surgery in type 2 diabetes. JAMA, 2020.
See also the Evidence Library and Sources & Verification.